The submission is for the same indications, including Xolair’s recently approved indication IgE-mediated food allergy.
Celltrion USA has submitted a biologics license application (BLA) for CT-P39, an interchangeable biosimilar that references Genentech’s Xolair (omalizumab).
The BLA submission includes results from a global phase 3 clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of CT-P39 compared with the reference product Xolair in patients with chronic spontaneous urticaria (CSU) up to Week 40.
In November 2023, Celltrion presented the primary results of its 12-week clinical trial during the American College of Allergy, Asthma and Immunology (ACAAI) conference.
The application includes the same indication as Xolair, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria and its recently approved indication IgE-mediated food allergy.
Last month, Xolair was approved to reduce allergic reactions, including anaphylaxis, that may occur in people with food allergies. Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterized by the rapid onset of symptoms following exposure to certain food allergens.
In Genetech’s study of Xolair, 67% of the 118 of the participants in the OUtMATCH trial who were treated with Xolair injections for between 16 and 20 weeks met the trial’s primary endpoint, which was consumption of 600 milligrams (mg) of peanut protein (about the amount in three to four peanuts) without moderate or severe allergic reaction (or combination of mild reactions). The reactions included hives, swelling, itching, throat tightness and abdominal pain, nausea or vomiting. Results were published in the New England Journal of Medicine (NEJM).
FDA Approves Xolremdi for Ultra Rare Immune Disorder
April 29th 2024Xolremdi is the first therapy for WHIM syndrome, which can cause recurrent lung infections and papillomavirus-related warts. It’s available in two doses: 400 mg for an annual cost of $496,400 and 300 mg for an annual cost of $372,300.
FDA Approves Pfizer’s Gene Therapy Beqvez for Hemophilia
April 26th 2024Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.